Immunogenic evaluation of a recombinant rabies virus expressing canine distemper virus H gene and canine parvovirus VP2 gene.

Multivalent recombinant vaccine candidate induces simultaneous protective immunity against three major canine diseases.

This study describes the development and evaluation of a novel recombinant rabies virus (rHEP-Flury(H+VP2)) engineered to express both canine distemper virus H gene and canine parvovirus VP2 gene. The recombinant virus was constructed by inserting these genes between the G and L genes of the HEP-Flury strain. Genetic stability testing demonstrated no deletions or mutations after 20 serial passages. Growth kinetics showed replication capacity comparable to the parental strain, though with marginally reduced peak titers. In immunogenicity studies using mice, inactivated rHEP-Flury(H+VP2) successfully induced neutralizing antibodies against all three target pathogens. Splenic lymphocyte analysis revealed significantly elevated interferon-gamma and interleukin-4 levels upon stimulation with inactivated virus preparations, indicating robust Th1 and Th2 cellular immune responses. These results demonstrate that this multivalent vaccine candidate can simultaneously generate protective immunity against rabies, canine distemper, and canine parvovirus, offering a promising approach to comprehensive canine disease prevention.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.